What is the current Price Target for the Galectin Therapeutics Inc. stock?

The average Galectin Therapeutics Inc. target price is $11.00. This is 752.71% higher than the current stock price. 1 Analyst has issued a Galectin Therapeutics Inc. price target 2026.

How high will the Galectin Therapeutics Inc. stock rise?

No reliable answer can be given as to how high the Galectin Therapeutics Inc. stock will rise. The performance of stocks, including the Galectin Therapeutics Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Galectin Therapeutics Inc. stock today?

The performance of Galectin Therapeutics Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Galectin Therapeutics Inc. stock fall?

The decline in Galectin Therapeutics Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Galectin Therapeutics Inc. Forecast, price target & analysts

$1.29

1.53% yesterday

Nasdaq, Jun 02, 10:08 pm CET

ISIN

US3632252025

Symbol

GALT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Galectin Therapeutics Inc. Target price 2025 - Analyst rating & recommendation

Galectin Therapeutics Inc. Classifications & Recommendation:

Hold

100%

Galectin Therapeutics Inc. Price Target

Target Price	$11.00
Price	$1.29
Potential	752.71% register free of charge
Number of Estimates	1

	1 Analyst has issued a Galectin Therapeutics Inc. price target 2026. The average Galectin Therapeutics Inc. target price is $11.00. This is 752.71% register free of charge higher than the current stock price.
	A rating was issued by 1 analysts: 0 Analysts recommend Galectin Therapeutics Inc. to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Galectin Therapeutics Inc. stock has an average upside potential 2026 of 752.71% register free of charge . Most analysts recommend the Galectin Therapeutics Inc. stock at Hold.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '24	2025 Estimates
EV/Sales		4.80

Galectin Therapeutics Inc....

Current Galectin Therapeutics Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Apr 02 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Dec 27 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Nov 15 2024

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Apr 02 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Dec 27 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Nov 15 2024

Discover more stocks with a high price target

NIO ADR 51.46%

Alibaba Group Holding Ltd 39.77%

TUI 37.83%

Novo Nordisk 36.18%

MongoDB 29.93%

Tencent Holdings Ltd. 28.03%

BYD 25.29%

NVIDIA 23.99%

BioNTech SE - ADR 20.70%

Pfizer 19.80%

Adidas 19.39%

Porsche 19.21%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now